ES2539405T3 - Vendaje para heridas biorresorbible - Google Patents

Vendaje para heridas biorresorbible Download PDF

Info

Publication number
ES2539405T3
ES2539405T3 ES12729582.2T ES12729582T ES2539405T3 ES 2539405 T3 ES2539405 T3 ES 2539405T3 ES 12729582 T ES12729582 T ES 12729582T ES 2539405 T3 ES2539405 T3 ES 2539405T3
Authority
ES
Spain
Prior art keywords
fibers
acid
wound dressing
gdf
bioresorbable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12729582.2T
Other languages
English (en)
Inventor
Frank PLÖGER
Denis Reibel
Dirk Grafahrend
Daniel NEUMÜLLER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Carl Freudenberg KG
Biopharm Gesellschaft zur Biotechnologischen Entwicklung von Pharmaka mbH
Original Assignee
Carl Freudenberg KG
Biopharm Gesellschaft zur Biotechnologischen Entwicklung von Pharmaka mbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Carl Freudenberg KG, Biopharm Gesellschaft zur Biotechnologischen Entwicklung von Pharmaka mbH filed Critical Carl Freudenberg KG
Application granted granted Critical
Publication of ES2539405T3 publication Critical patent/ES2539405T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/22Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
    • A61L15/32Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00Bandages or dressings; Absorbent pads
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • A61K38/1875Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/18Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing inorganic materials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/22Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/22Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
    • A61L15/32Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin
    • A61L15/325Collagen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42Use of materials characterised by their function or physical properties
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42Use of materials characterised by their function or physical properties
    • A61L15/425Porous materials, e.g. foams or sponges
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42Use of materials characterised by their function or physical properties
    • A61L15/44Medicaments
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42Use of materials characterised by their function or physical properties
    • A61L15/62Compostable, hydrosoluble or hydrodegradable materials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42Use of materials characterised by their function or physical properties
    • A61L15/64Use of materials characterised by their function or physical properties specially adapted to be resorbable inside the body
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/14Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • DTEXTILES; PAPER
    • D04BRAIDING; LACE-MAKING; KNITTING; TRIMMINGS; NON-WOVEN FABRICS
    • D04HMAKING TEXTILE FABRICS, e.g. FROM FIBRES OR FILAMENTARY MATERIAL; FABRICS MADE BY SUCH PROCESSES OR APPARATUS, e.g. FELTS, NON-WOVEN FABRICS; COTTON-WOOL; WADDING ; NON-WOVEN FABRICS FROM STAPLE FIBRES, FILAMENTS OR YARNS, BONDED WITH AT LEAST ONE WEB-LIKE MATERIAL DURING THEIR CONSOLIDATION
    • D04H1/00Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres
    • D04H1/04Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres from fleeces or layers composed of fibres having existing or potential cohesive properties, e.g. natural fibres, prestretched or fibrillated artificial fibres
    • D04H1/30Collagen
    • DTEXTILES; PAPER
    • D04BRAIDING; LACE-MAKING; KNITTING; TRIMMINGS; NON-WOVEN FABRICS
    • D04HMAKING TEXTILE FABRICS, e.g. FROM FIBRES OR FILAMENTARY MATERIAL; FABRICS MADE BY SUCH PROCESSES OR APPARATUS, e.g. FELTS, NON-WOVEN FABRICS; COTTON-WOOL; WADDING ; NON-WOVEN FABRICS FROM STAPLE FIBRES, FILAMENTS OR YARNS, BONDED WITH AT LEAST ONE WEB-LIKE MATERIAL DURING THEIR CONSOLIDATION
    • D04H1/00Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres
    • D04H1/40Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres from fleeces or layers composed of fibres without existing or potential cohesive properties
    • D04H1/42Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres from fleeces or layers composed of fibres without existing or potential cohesive properties characterised by the use of certain kinds of fibres insofar as this use has no preponderant influence on the consolidation of the fleece
    • D04H1/4266Natural fibres not provided for in group D04H1/425
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/252Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/412Tissue-regenerating or healing or proliferative agents
    • A61L2300/414Growth factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/602Type of release, e.g. controlled, sustained, slow
    • A61L2300/604Biodegradation

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Materials Engineering (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Textile Engineering (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Dispersion Chemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Vascular Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Surgery (AREA)

Abstract

Un tejido no tejido que comprende: fibras de una materia prima fibrosa que comprende polímeros biorresorbibles y/o biocompatibles, incluyendo las fibras al menos una sustancia biológicamente activa, que está distribuida en las fibras, en las que la sustancia biológicamente activa es una proteína relacionada con GDF-5, que es una proteína que comprende un dominio de nudo de cistina con una identidad de aminoácidos de al menos 60% con el dominio de nudo de cistina de 102 aa de GDF-5 humana según los aminoácidos 400-501 de SEC ID NO:2.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
5
15
25
35
45
E12729582
11-06-2015
unión dermoepitelial (Fitzpatrick y Rosen, J. Cosmet. Laser Ther, 5: 25-34 (2003)). Un cóctel (TNS Recovery Complex, SkinMedica, Inc. Carlsbad, CA, USA) que contiene siete citocinas (VEGF, IL-6 y -8, HGF, PDGF-a, GCSF, y TGF-1) derivadas de fibroblastos de prepucio neonatal se ensayó en un estudio multicéntrico. La evaluación mostró mejora en la textura de la piel, y menor número de arrugas (Rokhsar, C.K. et al., Dermatol. Surg. 31: 11661178 (2005)). El factor de crecimiento epidérmico recombinante (ReVive Skincare) y el factor de crecimiento vegetal N-furfuriladenina (quinetina) también están en el mercado. Todas estas proteínas se pueden usar junto con las proteínas relacionadas con GDF-5 de la invención. Otras proteínas que actúan sinérgicamente si se combinan con proteínas relacionadas con GDF-5 se describen en la bibliografía/patentes, por ejemplo en el documento WO 99/15191. Se prefieren neurotrofinas, proteínas hedgehog y proteínas de la familia del factor de crecimiento transformante, incluyendo, pero sin limitarse a, TGF-alfas, TGF-betas, activinas, BMPs y GDFs. Se prefiere especialmente una combinación con una cualquiera de EGF, TGF-1, TGF-2, TGF-3, NGF y/o GDNF.
Otros componentes aceptables en los tejidos son:
-Retinoides (derivados de vitamina A) que conservan la integridad de las superficies mucosales/epiteliales;
-Hidroxiácidos (ácidos carboxílicos orgánicos clasificados además en alfa-hidroxiácidos (AHA) y betahidroxiácidos (BHA)) que potencian el desprendimiento epidérmico, es decir, ácido glicólico, ácido láctico, ácido cítrico, ácido mandélico, ácido málico, y ácido tartárico;
-Antioxidantes que contrarrestan los efectos dañinos de radicales libres, es decir, vitamina C, vitamina E, pantenol, ácido lipoico, ubiquinona, niacinamida, dimetilaminoetanol, trampas de espín, melatonina, catalasa, glutationa, superóxido dismutasa, peroxidasa, glucopiranósidos, polifenoles, cisteína, alantoína, furfuriladenina, ácido úrico, y carnosina;
-Agentes despigmentantes que alivian la hiperpigmentación, es decir, N-acetil-4-S-cisteanimilfenol, ácido kójico, arbutina, ácido azaleico, compuesto de la morera del papel, agentes exfoliantes químicos (resorcinol, ácido salicílico), fórmula de Kligman, fórmula de Pathak, y fórmula de Westerhofs;
-Sustancias botánicas, es decir, camomila, ginseng, gingko biloba, curcumina, glicirricina, capsaicina, y aloe vera;
-Glucosaminoglicanos que apoyan la regeneración epidérmica, es decir, ácido hialurónico;
-Anticelulíticos que median la lipolisis, es decir, estimulantes beta-adrenérgicos tales como teobromina, teofilina, aminofilina, cafeína, epinefrina, y estimulantes alfa1-adrenérgicos tales como yohimbina, piperoxano, y fentolamina;
-Hormonas, es decir, estrógenos, progesterona, testosterona, y hormona del crecimiento;
-Agentes antimicrobianos, es decir, triclosán, clorhexidina, povidona yodada, peróxido de hidrógeno, preparaciones anticaspa, cinc piritiona;
-Filtros químicos de la radiación UV, es decir, 3-benciliden alcanfor (3-BC) o 4-metilbenciliden alcanfor (4-MBC);
-Además, tampones, estabilizantes, conservantes, agentes reductores, agentes quelantes antioxidantes, agentes que modifican la isotonicidad, desodorantes, anestésicos, adyuvantes, y aditivos que potencian la solubilidad.
Estos son solamente ejemplos no limitantes de posibles aditivos, y un trabajador experto en la técnica puede añadir fácilmente otros excipientes que están actualmente en uso que son considerados generalmente como seguros. Para más información sobre métodos para formular una composición farmacéutica y la selección de sustancias farmacéuticamente aceptables, por favor véanse, por ejemplo, Remington’s Pharmaceutical Sciences (luth ed.; Mack Publishing Company, Eaton, Pennsylvania, 1990), Wang et al. (1980), J. Parent. Drug Assn. 34 (6): 452-462 (1980); Wang et al. (1988), J. Parent. Sci. and Tech. 42: 4-26; Lachman et al. (1968), Drug and Cosmetic Industry 102(1): 36-38, 40 y 146-148; y Akers (1988)J. Parent. Sci. and Tech. 36 (5): 222-228.
Preferiblemente se eluye entre 1% y 100% de la sustancia biológicamente activa desde el tejido no tejido durante 3 a 7 días en contacto con fluidos corporales, plasma, medios o disolución tampón. Lo más preferible, se libera entre 10% y 100% de la sustancia bioactiva en condiciones fisiológicas (tampón PBS, suero fetal de ternera al 10%, 37ºC).
Las siguientes figuras, ejemplos y protocolos de secuencias están destinadas a ilustrar adicionalmente la invención.
SEC ID NO: 1 muestra la secuencia de ADN, y SEC ID NO: 2 muestra la secuencia proteica del precursor de GDF-5 humana.
SEC ID NO: 3 muestra la secuencia de ADN, y SEC ID NO: 4 muestra la secuencia proteica de la GDF-5 monómera madura humana.
8
imagen7
imagen8
imagen9

Claims (1)

  1. imagen1
ES12729582.2T 2011-06-22 2012-06-21 Vendaje para heridas biorresorbible Active ES2539405T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11170971 2011-06-22
EP11170971A EP2537538A1 (en) 2011-06-22 2011-06-22 Bioresorbable Wound Dressing
PCT/EP2012/061965 WO2012175611A1 (en) 2011-06-22 2012-06-21 Bioresorbable wound dressing

Publications (1)

Publication Number Publication Date
ES2539405T3 true ES2539405T3 (es) 2015-06-30

Family

ID=46354320

Family Applications (1)

Application Number Title Priority Date Filing Date
ES12729582.2T Active ES2539405T3 (es) 2011-06-22 2012-06-21 Vendaje para heridas biorresorbible

Country Status (13)

Country Link
US (3) US9278156B2 (es)
EP (2) EP2537538A1 (es)
JP (1) JP6138773B2 (es)
KR (1) KR101964482B1 (es)
CN (1) CN103874516B (es)
AU (1) AU2012274046C1 (es)
BR (1) BR112013032714A2 (es)
CA (1) CA2839142C (es)
ES (1) ES2539405T3 (es)
RU (1) RU2577155C2 (es)
TW (1) TWI572336B (es)
WO (1) WO2012175611A1 (es)
ZA (1) ZA201309341B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9999702B2 (en) * 2010-04-09 2018-06-19 Kci Licensing Inc. Apparatuses, methods, and compositions for the treatment and prophylaxis of chronic wounds
EP2537538A1 (en) 2011-06-22 2012-12-26 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka mbH Bioresorbable Wound Dressing
US11173227B2 (en) 2013-05-22 2021-11-16 The Penn State Research Foundation Wound dressings and applications thereof
DK3427726T3 (da) * 2016-03-07 2023-05-15 Univ Osaka Ark med vedvarende lægemiddelfrigvelse til behandling af nerveskade
FR3058041B1 (fr) 2016-10-28 2021-06-04 Centre Hospitalier Regional Univ Lille Dispositif apte a etre implante dans le corps d'un sujet pour former un implant - masse tissulaire et procede associes.
AU2018266546B2 (en) 2017-05-07 2024-06-13 Locus Ip Company, Llc Cosmetic compositions for skin health and methods of using same
EP3703633B2 (en) 2017-11-03 2024-06-26 3M Innovative Properties Company Extended wear-time dressing
CN108210979B (zh) * 2018-01-28 2020-09-29 山东东贝医药科技有限公司 一种医用杀菌纤维敷料
CN108286132B (zh) * 2018-03-27 2020-06-23 界首市圣通无纺布有限公司 一种具有抗菌功能的易降解无纺布加工方法
CA3107300A1 (en) 2018-05-25 2019-11-28 Locus Ip Company, Llc Therapeutic compositions for enhanced healing of wounds and scars
CN108893792B (zh) * 2018-07-13 2020-11-03 深圳大学 生物活性纤维及其制备方法、应用和制备系统
BR112021024419A2 (pt) * 2019-06-03 2022-01-18 Convatec Ltd Métodos e dispositivos para desfazer e confinar patógenos
US20220409769A1 (en) * 2019-09-17 2022-12-29 Mayo Foundation For Medical Education And Research Methods and materials for treating fistulas
WO2022138206A1 (ja) * 2020-12-22 2022-06-30 日本毛織株式会社 創傷被覆材
US20240091404A1 (en) * 2021-02-09 2024-03-21 Shin-Etsu Chemical Co., Ltd. Gelatin-containing device

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19525416A1 (de) 1995-07-12 1997-01-16 Bioph Biotech Entw Pharm Gmbh Verwendung von MP52 zur Behandlung und Prävention von Erkrankungen des Nervensystems
JP3193050B2 (ja) 1992-02-12 2001-07-30 ビオファルム ゲゼルシャフト ツア ビオテヒノロ ギッシェン エントヴィックルング フォン ファル マカ ミット ベシュレンクテル ハフツング 新規の増殖/分化因子をコード化するdna配列
WO1994015949A1 (en) 1993-01-12 1994-07-21 Johns Hopkins University School Of Medicine Growth differentiation factor-5
IL110589A0 (en) 1993-08-10 1994-11-11 Bioph Biotech Entw Pharm Gmbh Growth/differentiation factor of the TGF- beta family
ES2255059T3 (es) 1993-12-07 2006-06-16 Genetics Institute, Llc Bmp-12, bmp-13 y composiciones suyas inductoras de tendon.
AU1120295A (en) 1994-11-07 1996-05-31 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Cartilage-derived morphogenetic proteins
JPH08209435A (ja) * 1995-01-30 1996-08-13 Sangi Co Ltd 生体適合糸
PL186518B1 (pl) 1995-04-19 2004-01-30 Bioph Biotech Entw Pharm Gmbh Białko, kompozycja farmaceutyczna i sposób wytwarzania białka
PT831884E (pt) 1995-06-05 2003-11-28 New York Society Uso de proteinas morfogeneticas do caso para cicatrizacao e reparacao da ligacao do tecido conjuntivo
JPH0931098A (ja) 1995-07-24 1997-02-04 Hoechst Japan Ltd 新規なタンパク質hmwヒトmp52
ZA966489B (en) 1995-08-03 1997-02-26 Bioph Biotech Entw Pharm Gmbh New protein human MP52 Arg.
DE19647853A1 (de) * 1996-11-19 1998-05-20 Bioph Biotech Entw Pharm Gmbh Verbindungen mit verbesserter knorpel- und/oder knocheninduzierender Aktivität
JPH11335398A (ja) 1998-05-22 1999-12-07 Hoechst Marion Roussel Kk 新規な骨誘導活性を有する単量体蛋白質およびそれらからなる軟骨・骨疾患の予防および治療薬
EP1074620A1 (en) 1999-08-06 2001-02-07 HyGene AG Monomeric protein of the TGF-beta family
CA2301693A1 (en) 1997-09-19 1999-04-01 Klaus Unsicker Cytokines having neurotrophic activity
US6992066B2 (en) * 1998-10-16 2006-01-31 Zimmer Orthobiologics, Inc. Povidone-containing carriers for polypeptide growth factors
US7020845B1 (en) * 1999-11-15 2006-03-28 Gottfurcht Elliot A Navigating internet content on a television using a simplified interface and a remote control
EP1372698A2 (en) 2001-03-23 2004-01-02 BIOPHARM GESELLSCHAFT ZUR BIOTECHNOLOGISCHEN ENTWICKLUNG VON PHARMAKA mbH Use of cytokines of the tgf-beta superfamily for the treatment and diagnosis of skin related disorders
WO2004000915A2 (en) * 2002-06-24 2003-12-31 Tufts University Silk biomaterials and methods of use thereof
TW200410714A (en) 2002-08-07 2004-07-01 Smithkline Beecham Corp Electrospun amorphous pharmaceutical compositions
EP1462126A1 (en) 2003-03-28 2004-09-29 BIOPHARM GESELLSCHAFT ZUR BIOTECHNOLOGISCHEN ENTWICKLUNG VON PHARMAKA mbH Improved Osteoinductive Materials
JP2005005144A (ja) * 2003-06-12 2005-01-06 Nemoto:Kk スイッチカバー
US7704740B2 (en) * 2003-11-05 2010-04-27 Michigan State University Nanofibrillar structure and applications including cell and tissue culture
JP4618997B2 (ja) * 2003-12-09 2011-01-26 テルモ株式会社 ステントおよびその製造方法
US8221780B2 (en) * 2004-04-20 2012-07-17 Depuy Mitek, Inc. Nonwoven tissue scaffold
EP1698691A1 (en) * 2005-03-04 2006-09-06 Biopharm Gesellschaft zur biotechnologischen Entwicklung von Pharmaka mbH Growth factor mutants with improved biological activity
JP2006254722A (ja) * 2005-03-15 2006-09-28 Toray Ind Inc 細胞足場材料
DE102005048939A1 (de) 2005-07-01 2007-01-11 Carl Freudenberg Kg Vorrichtung, Anordnung und Verfahren zur Herstellung von Fasern und eine solche Fasern umfassende Anordnung
US20100303881A1 (en) 2006-02-02 2010-12-02 The John Hopkins University Therapeutic Electrospun Fiber Compositions
EP1880731A1 (en) 2006-07-18 2008-01-23 BIOPHARM GESELLSCHAFT ZUR BIOTECHNOLOGISCHEN ENTWICKLUNG VON PHARMAKA mbH Human growth and differentiation factor GDF-5
WO2008093341A2 (en) * 2007-01-31 2008-08-07 Technion Research & Development Foundation Ltd. Electrospun scaffolds and methods of generating and using same
DE102007011606A1 (de) * 2007-03-02 2008-09-04 Carl Freudenberg Kg Faser-Wirrgelege
KR101538981B1 (ko) 2007-09-13 2015-07-23 드레징 인터내셔널 엔. 브이. 준설을 최적화하기 위한 시스템 및 방법
DE102007044648B4 (de) * 2007-09-18 2020-11-26 Carl Freudenberg Kg Bioresorbierbarer Gelatinevliesstoff
US20090163936A1 (en) 2007-12-21 2009-06-25 Chunlin Yang Coated Tissue Engineering Scaffold
US20100002151A1 (en) * 2008-07-01 2010-01-07 Yang Pan Handheld media and communication device with a detachable projector
US7644955B1 (en) * 2008-07-03 2010-01-12 Naris Komolrochanaporn Quick coupling type fitting
US8557271B2 (en) * 2008-07-16 2013-10-15 Warsaw Orthopedic, Inc. Drug depot implantable within a joint
TWM370392U (en) * 2009-06-19 2009-12-11 zhi-sheng Chen Curative ventilating dressing
EP2598177B1 (en) * 2010-07-30 2015-06-17 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka mbH Drug delivery devices and growth factor formulations for accelerated wound healing
EP2537538A1 (en) 2011-06-22 2012-12-26 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka mbH Bioresorbable Wound Dressing

Also Published As

Publication number Publication date
US9782511B2 (en) 2017-10-10
AU2012274046B2 (en) 2016-02-18
CN103874516A (zh) 2014-06-18
BR112013032714A2 (pt) 2017-01-24
US20180008743A1 (en) 2018-01-11
ZA201309341B (en) 2015-11-25
KR101964482B1 (ko) 2019-04-01
CA2839142C (en) 2019-04-16
KR20140146035A (ko) 2014-12-24
CA2839142A1 (en) 2012-12-27
TWI572336B (zh) 2017-03-01
WO2012175611A1 (en) 2012-12-27
US20160199530A1 (en) 2016-07-14
RU2014101762A (ru) 2015-07-27
AU2012274046C1 (en) 2016-07-14
EP2537538A1 (en) 2012-12-26
CN103874516B (zh) 2016-06-01
TW201302170A (zh) 2013-01-16
US9278156B2 (en) 2016-03-08
AU2012274046A1 (en) 2014-01-23
JP6138773B2 (ja) 2017-05-31
US20140141050A1 (en) 2014-05-22
RU2577155C2 (ru) 2016-03-10
EP2723408B1 (en) 2015-04-15
EP2723408A1 (en) 2014-04-30
JP2014522918A (ja) 2014-09-08

Similar Documents

Publication Publication Date Title
ES2539405T3 (es) Vendaje para heridas biorresorbible
Mohanty et al. A human epidermal growth factor-curcumin bandage bioconjugate loaded with mesenchymal stem cell for in vivo diabetic wound healing
BR112013020005A2 (pt) peptídeo de fórmula geral r1-wn-xm-aa1-aa2-aa3-aa4-aa5-aa6-yp-zq-r2, seus estereoisômeros, misturas dos mesmos e/ou seus sais cosmética ou farmaceuticamente aceitáveis e composição cosmética ou farmacêutica
BRPI0913831B8 (pt) peptídeo com a fórmula geral (i), seus estereoisômeros, suas misturas, ou seus sais cosmética ou farmaceuticamente aceitáveis, processo para a preparação de um peptídeo com a fórmula geral (i), seus estereoisômeros, suas misturas, ou seus sais cosmética ou farmaceuticamente aceitáveis e composição cosmética ou farmacêutica
Ookubo et al. The transdermal inhibition of melanogenesis by a cell-membrane-permeable peptide delivery system based on poly-arginine
KR102359387B1 (ko) 줄기세포 유래의 엑소좀을 유효성분으로 포함하는 피지분비 감소용 조성물
US9815878B2 (en) Use of PEDF-derived polypeptides for preventing and/or ameliorating skin aging
MX2011008616A (es) Peptidos utiles en el tratamiento y/o cuidado de la piel , mucosas y/o cuero cabelludo y su uso en composiciones cosmeticas o farmaceuticas.
WO2017164609A3 (ko) 피부 재생 또는 상처 치료용 펩타이드 및 이의 용도
KR101592864B1 (ko) 상처 치료 또는 상처 치료 촉진용 약학 조성물
US20220079990A1 (en) Methods and compositions for treating skin and hair disorders
JP2016501866A5 (es)
CN108992384A (zh) 一种治疗黄褐斑的敷料
EA201590546A1 (ru) Способы лечения заболеваний, связанных с волосами
JP2015528479A5 (es)
MX336278B (es) Composiciones y metodos para la prevencion y el tratamiento de heridas.
ES2887588T3 (es) Composiciones derivadas de pasta de fracción de Cohn y uso de las mismas
Li et al. Umbilical cord‐derived mesenchymal stem cell secretome promotes skin regeneration and rejuvenation: From mechanism to therapeutics
KR20220011861A (ko) 줄기세포 유래의 엑소좀 또는 이의 동결건조제제를 유효성분으로 포함하는 항암제나 방사선 조사로 인한 피부특이반응의 예방, 억제, 완화, 개선 또는 치료용 조성물
CN105055187B (zh) 一种面部年轻化美容制剂及其制备方法
CN118043341A (zh) 具有抗老化活性的肽及其用途
KR102209294B1 (ko) 줄기세포 유래 엑소좀의 동결건조제제 및 이를 유효성분으로 포함하는 발모 촉진 또는 탈모 방지용 조성물
EA201591095A1 (ru) Белок slurp-1 для применения в лечении глазных болезней
JP2015537028A5 (es)
RU2018146294A (ru) Композиция для лечения уремического зуда